- Home
- KURA vs CHI Comparison
KURA vs CHI Comparison
Compare KURA & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$8.35
Company Overview
Basic Information| Metric | KURA | CHI |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 830.1M | 882.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KURA | CHI |
|---|---|---|
| Price | $8.35 | $11.69 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $26.88 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 186.2K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,029,000.00 | N/A |
| Revenue This Year | $88.72 | N/A |
| Revenue Next Year | $68.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $9.70 |
| 52 Week High | $12.49 | $11.61 |
Technical Indicators
Market Signals| Indicator | KURA | CHI |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 57.42 |
| Support Level | $7.50 | $11.00 |
| Resistance Level | $8.08 | $11.60 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 68.99 | 65.00 |
Price Performance
Historical Comparison KURA
CHI
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.